SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as President Trump's threats of new tariffs on European nations over Greenland escalate geopolitical tensions, leading to a risk-off market sentiment. The community is divided, with some anticipating a significant market pullback, while others view it as a 'buy the dip' opportunity, also noting a Japan-led bond sell-off as a contributing factor. This environment is fueling discussions about broader market volatility and a flight to safe-haven assets.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following constructive discussions with the FDA regarding a resubmission path for ANKTIVA in bladder cancer, complemented by significant international approvals and strategic partnerships like those recently established in Saudi Arabia for broader cancer indications. This development, coupled with high short interest, is fueling widespread community excitement about a potential paradigm shift in oncology and intense speculation regarding a short squeeze amidst growing calls for expedited access to these innovative treatments.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is actively trending amid escalating US-EU trade tensions driven by President Trump's tariff threats over Greenland, sparking a widespread market sell-off and global risk-off sentiment. The investment community is sharply divided between those anticipating a deeper correction for technology and growth stocks and fervent "buy the dip" proponents. Immediate market focus remains on an upcoming Supreme Court ruling regarding tariff authority and a heavy week of earnings reports, amplifying uncertainty.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is a major talking point following its J.P. Morgan conference appearance, where investors are eagerly seeking clarity on its strategy for advancing the Matrix-M adjuvant technology and securing new collaborations. Community sentiment is sharply focused on management's pace in realizing pipeline potential, including a recent Pfizer agreement and ongoing Sanofi ventures, with an activist investor's growing stake and significant short interest adding to the intense market watch.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending after announcing positive data from its placebo-controlled Phase 1 clinical trial of soquelitinib for atopic dermatitis, showing strong efficacy. The community is actively discussing the oral ITK inhibitor's potential in a large market, with many anticipating significant revaluation and partnership opportunities for its novel mechanism of action.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is gaining significant attention as its patented Optical Interposer platform is seen as crucial for next-generation AI and data center infrastructure, enabling highly efficient and scalable optical interconnects. The community is actively discussing recent product innovation awards and confirmed partnerships, including with Celestial AI (now Marvell), which validate its technology. Anticipation is also building for the imminent disclosure of major institutional investors, signaling strong long-term confidence.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending amid intense debate surrounding the Federal Reserve's independence, fueled by a federal probe into its Chair and the administration's aggressive policy maneuvers impacting bond markets. Investors are actively discussing whether long-term treasuries offer a crucial hedge against a potential economic slowdown or face further headwinds from escalating national debt and geopolitical uncertainty.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors react to a significant patent extension for its key products until 2041, coupled with a bullish preliminary business update accelerating IBSRELA's path to $1 billion in revenue by 2029 and multiple analyst price target upgrades. The community is buzzing with renewed acquisition speculation and optimism over the company's long-term value, despite ongoing discussions about short-term price fluctuations attributed to market dynamics. This confluence of positive developments has many viewing Ardelyx as a significantly undervalued biotech with strong commercial execution.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin (APP) is actively trending amid recent allegations of money laundering and illicit financial ties, triggering a sharp sell-off across the stock. Despite this, community sentiment is divided, with many dismissing the claims as a coordinated short attack ahead of strong earnings, while others are seizing the opportunity to buy into the fundamentally strong AI-powered ad platform.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is seeing heightened conversation due to recent developments surrounding Trump's assertive stance on Greenland and reactions to a perceived Nobel Peace Prize snub, which has sparked discussions of new tariffs on European nations. The community is actively debating the potential for increased market volatility, geopolitical instability, and the broader economic ramifications of these actions. This ongoing dialogue underscores intense political polarization and its influence on market sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Quality Over Hype: Investing Wisely for the Long Term

Nancy Tengler shares her market outlook and favorite stocks.

Retail sentiment for American Express brightened on Friday after the firm raised its full year earnings guidance while reporting a mixed set of earnings. The credit card giant raised its full-year earnings per share (EPS) guidance to $13.30 - $13.80 from $12.65 - $13.15 previously.American Express also stated that it continues to expect revenue growth in line with the guidance range of 9%to 11% set at the beginning of the year. Retail sentiment on the stock is currently trending in bullish territory (60/100) supported by an extremely high message volume.<figure class="image"><img style="aspect-ratio:787/236;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_19_at_9_49_19_AM_97f070487a.png" alt="Retail sentiment for American Express stock trends in bullish territory" width="787" height="236"><figcaption>Retail sentiment for American Express stock trends in bullish territory</figcaption></figure>For the second quarter, the firm reported a 9% rise in its total revenues net of interest expense (forex adjusted) at $16.33 billion, which came in lower than a Street estimate of $16.59 billion. American Express said the rise in revenues was primarily driven by higher net interest income, increased card member spending, and continued strong card fee growth.Network volumes increased 3% YoY to $440.60 billion during the quarter. The average fee per card increased to $101 compared to $91 in the same period last year. Active spending by the firm’s premium customers at a time when recession fears are fading has helped the firm keep up the earnings.Stephen J. Squeri, Chairman and Chief Executive Officer at American Express said that an increased scale, combined with premium, high credit quality customers, well-controlled expense base and successful investments to continuously enhance the firm’s membership model, fuels the earnings power of the core business. This has reinforced the company’s confidence in its ability to deliver strong bottom-line growth, he said.Earnings per share rose 21% year-over-year (YoY) to $3.49, higher than a Street estimate of $3.24. Net income rose 39% YoY to $3.02 billion.Amidst all the upbeat numbers, the only blip was an increase in the consolidated provisions for credit losses that came in at &nbsp;$1.30 billion, compared with $1.20 billion a year ago. The increase reflected higher net write-offs, partially offset by a lower reserve build YoY, the firm said.Squeri added that based on the strong performance of its core business, the firm believes it can increase its marketing investments by around 15% YoY without using any of the transaction gain, allowing it to drive the “profitable growth” that investors love to see.American Express shares were trading nearly 2% lower in Friday’s pre-market session. The stock has performed well this year, having returned over 32% on a year-to-date basis. Based on current retail sentiment, it’s likely that at least some investors are looking to use this weakness to add to their longer-term positions.&nbsp;&nbsp;

Why American Express Drew Positive Retail Sentiment After Earnings Announcement

Although revenue came in lower than a Street estimate, its second quarter earnings beat estimates and the firm raised its full-year earnings guidance. 

Equity

Although revenue came in lower than a Street estimate, its second quarter earnings beat estimates and the firm raised its full-year earnings guidance. Retail investors and traders remain upbeat about the firm’s longer-term bet on the higher-income consumer.

TGLR
ETF Opportunities Trust - LAFFER TENGLER Equity Income ETF

Feed

News

Sentiment

Fundamentals

Info

Latest TGLR News

TGLRETF Opportunities Trust - LAFFER TENGLER Equity Income ETF